Core Viewpoint - The European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed after at least one prior systemic therapy other than somatostatin analogues [1] Company Summary - Ipsen is a global biopharmaceutical company focused on delivering transformative medicines in oncology, rare diseases, and neuroscience [11] - The company has a commitment to innovation and aims to make Cabometyx available to more patients, reinforcing its dedication to oncology therapies [3] Industry Summary - Neuroendocrine tumors (NETs) develop slowly and can originate from various body parts, requiring multiple lines of therapy as the disease progresses [2] - Treatment options for patients with lung NETs are particularly limited, with 27% of diagnosed individuals having no approved options upon progression [2] - The CABINET Phase III trial demonstrated significant benefits for Cabometyx, showing a 77% reduction in the risk of disease progression or death in advanced pNETs and a 62% reduction in epNETs compared to placebo [5] - The approval of Cabometyx is expected to provide a unique treatment option for patients with limited alternatives, addressing a significant unmet need in the NET treatment landscape [3][4]